Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Published on by Cell Biologist

Dr. Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Dr. Herbeuval Jean-Philippe | CNRS | France

Jean-Philippe Herbeuval is a French immunologist and CNRS Director of Research, renowned for pioneering contributions to translational immunology and biomedical innovation. A PhD holder in immuno-oncology, he completed a prestigious Fogarty Fellowship at the NIH, USA, where he earned the Norman P. Salzman Award. He founded and leads the CBMIT team at Université Paris Cité, integrating immunology, virology, and chemistry for therapeutic discovery. Herbeuval has launched two biotech companies: Ermium Therapeutics, based on anti-interferon therapies, and Elyris Pharma, centered on PDK1 as a novel anti-inflammatory target. With 9 patents (3 licensed), €8.8M in research funding, and >70 publications (h-index 28), his innovations span diagnostics to therapeutics. He also contributes to policy and innovation strategy through national and international committees. Recognized for his vision, leadership, and mentorship, Herbeuval exemplifies the intersection of academic research and impactful biotechnology entrepreneurship.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Exceptional Innovation in Immunology & Therapeutics

    • Discovered key therapeutic targets such as CXCR4 and PDK1.

    • Founded Ermium Therapeutics (2019) and Elyris Pharma (2024), securing over €12M in funding.

    • Holds 9 patents, with 3 already licensed — a key indicator of translational success.

  2. Proven Scientific Leadership

    • Director of Research (CNRS), Head of CBMIT at Université Paris Cité.

    • Established and led multiple interdisciplinary research teams and platforms (Cyto2BM, CBMIT).

    • Supervised 10 PhD students, 7 postdocs, and over 18 master’s students, many of whom reached elite positions.

  3. High-Impact Research Output

    • 70+ publications, including high-citation studies on interferon signaling in HIV.

    • Over 3,500 citations, h-index: 28 — showing strong impact and visibility.

  4. Strong National and International Recognition

    • Winner of the prestigious i-Lab National Innovation Prize (France, 2019).

    • Invited speaker at over 24 international conferences; reviewer for Nature Medicine and PNAS.

    • Advisor for funding agencies across the US (NIH), UK (MRC), China, and Brazil.

  5. Valuable Public and Government Engagement

    • CNRS Innovation Ambassador (2024) and expert for multiple national programs (ANRS, Campus France).

    • Actively engages in public science communication (TV, radio, press).

🔧 Areas for Improvement:

  1. Scaling Global Industry Impact

    • While Ermium and Elyris are high-potential, further proof of market adoption and therapeutic success will solidify his innovation leadership globally.

  2. Broader Patent Commercialization

    • More patents could potentially be moved from licensing to full-scale clinical trials or product development phases.

  3. Diversity of Therapeutic Areas

    • While the focus on interferon biology and immunomodulation is powerful, broader expansion into other disease domains (e.g., neuroinflammation, metabolic syndromes) could enhance reach.

🎓 Education:

Jean-Philippe Herbeuval earned his PhD in immuno-oncology in 2001 from Université Jean Monnet, Saint-Étienne, working under the INSERM network. He then pursued a highly competitive five-year Fogarty Postdoctoral Fellowship at the National Institutes of Health (NIH), USA, under Dr. Gene Shearer, focusing on the antiviral response to HIV. During this time, he earned multiple prestigious awards including the Norman P. Salzman Award and an NIH Young Scientist Cash Award. Upon returning to France, he secured a CNRS Junior PI position in 2006 and received his Habilitation to Direct Research (HDR) in 2008 from Université Paris Descartes. His rapid career progression continued with his appointment as Director of Research (2nd class) in 2013 and promotion to 1st class in 2019 at CNRS UMR8601. His educational path reflects an exceptional blend of scientific rigor, international exposure, and leadership in innovation.

💼 Experience:

Jean-Philippe Herbeuval brings over two decades of distinguished experience at the interface of academic research and biotech innovation. Starting with his postdoctoral fellowship at NIH (2001–2006), he led groundbreaking studies on interferon responses in HIV. Since 2006, he has served within CNRS, creating and leading the CBMIT interdisciplinary team. He established the Cyto2BM core facility and spearheaded multiple translational projects. As scientific founder of Ermium Therapeutics (2019) and Elyris Pharma (2024, in progress), he has successfully attracted venture capital and secured technology transfer agreements. His strategic involvement extends to national innovation committees (ANRS, CNRS, Campus France) and advisory roles. He has trained over 35 researchers and supervised major national/international grants. Notably, he combines deep scientific insight with an entrepreneurial mindset, as shown by his participation in Deeptech Founders and RISE programs. His experience spans leadership, translational science, investment negotiations, and scientific mentoring.

🔬 Research Focus:

Jean-Philippe Herbeuval’s research is centered on translational immunology, particularly type I interferons, autoinflammatory pathways, and host-pathogen interactions. His work explores immune dysregulation in infectious diseases such as HIV, SARS-CoV-2, dengue, and influenza, with a special focus on the immune-modulatory roles of dendritic cells and apoptotic pathways. He has identified novel therapeutic targets including CXCR4 and PDK1, leading to two biotech start-ups and multiple patents. His interdisciplinary CBMIT team integrates immunology, virology, medicinal chemistry, and computational modeling to develop innovative therapeutic strategies and biomarkers. He has a keen interest in immunomodulation, therapeutic interference with IFN pathways, and discovery of druggable checkpoints in innate immunity. With over 70 peer-reviewed publications, his scientific output has shaped current understanding of immune pathogenesis and opened new avenues for therapy in inflammatory and infectious diseases. His approach bridges fundamental research with practical applications in drug discovery and biotech development.

📚 Publications Top Notes:

  1. 🧬 HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

  2. ⚰️ CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon–dependent, TRAIL/DR5-mediated apoptosis

  3. 🚻 Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women

  4. 🧪 HIV-1 immunopathogenesis: how good interferon turns bad

  5. 🔄 Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells

  6. 🧠 Differential expression of IFN-α and TRAIL/DR5 in lymphoid tissue of progressor vs. nonprogressor HIV-1-infected patients

  7. 🧟 HIV turns plasmacytoid dendritic cells into TRAIL-expressing killer pDC via TLR7-induced IFN-α

  8. 🧬 Regulation of TRAIL on primary CD4+ T cells by HIV-1: role of plasmacytoid dendritic cells

  9. 💉 TRAIL in HIV-1–infected patients and its production by antigen-presenting cells

  10. 🧫 Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6

🧾 Conclusion:

Dr. Jean-Philippe Herbeuval stands out as a highly qualified and deserving candidate for the Best Innovator Award. His rare combination of scientific excellence, translational innovation, entrepreneurial leadership, and mentorship places him in the top tier of biomedical innovators. His work not only bridges science and industry but also directly contributes to addressing global health challenges. Continued support and recognition of his efforts will likely catalyze further innovation in therapeutic immunology.

Fani Pantouli | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Dr. Fani Pantouli | Immunology Cellular Interactions | Best Researcher Award

Dr. Fani Pantouli, Cleveland Clinic Florida Research and Innovation Center, United States

Dr. Fani Pantouli is a passionate and results-driven research scientist with deep expertise in neuroscience, pharmacology, immunology, and oncology. A USA permanent resident, she currently serves as a Postdoctoral Fellow at the Cleveland Clinic Florida Research and Innovation Center. Her work bridges cutting-edge vaccine development and cancer therapeutics, contributing significantly to preclinical and translational research. Dr. Pantouli’s scientific approach blends in vivo and in vitro techniques to uncover therapeutic pathways, particularly in head and neck cancer and viral immunology. Her interdisciplinary knowledge is reflected in a growing portfolio of peer-reviewed publications addressing pressing biomedical challenges, from COVID-19 immunity to neuropsychiatric disorders. She is known for her innovative methodologies, collaborative mindset, and unwavering dedication to advancing human health. Dr. Pantouli’s work is making a meaningful impact on personalized medicine and translational therapeutics, positioning her as a rising leader in biomedical research.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Multidisciplinary Expertise
    Dr. Pantouli integrates neuroscience, immunology, pharmacology, and oncology into her research, making her contributions uniquely cross-disciplinary and impactful.

  2. High-Impact Research in Vaccine Development
    Her postdoctoral work on COVID-19 and respiratory viruses, particularly her development of T-cell profiling and viral neutralization assays, directly informs global efforts in personalized vaccine design.

  3. Innovative Cancer Models
    She developed a novel in vivo murine model for head and neck squamous cell carcinoma, advancing drug screening for p53-related targets. This is vital in understanding and treating cancers with p53 mutations.

  4. Robust Publication Record
    Dr. Pantouli has authored or co-authored multiple peer-reviewed articles in reputable journals (e.g., Vaccines, Neuropsychopharmacology), with several under review in top-tier outlets like Science and Journal of Biological Psychiatry.

  5. Focus on Health Equity
    Her research into ethnic differences in immune response underscores a strong commitment to inclusive and equitable healthcare.

  6. Experience in Preclinical & Translational Research
    Her hands-on experience building disease models and testing therapeutic strategies bridges basic science and clinical application—core to translational medicine.

⚠️ Areas for Improvement:

  1. Independent Research Leadership
    While she has made significant contributions as a postdoctoral fellow, moving toward independent investigator roles (e.g., PI on grants) would strengthen her candidacy.

  2. Visibility and Recognition
    Increased presence in international symposia, keynote talks, or award recognitions would help boost her visibility within the scientific community.

  3. Mentorship and Community Involvement
    Involvement in mentoring junior researchers or leading educational outreach initiatives could further showcase her leadership potential.

🎓 Education:

Dr. Pantouli holds a Ph.D. in Neuropharmacology from the University of Surrey and St. George’s University of London, awarded between 2014 and 2017. Her doctoral studies explored neural mechanisms underpinning pharmacological and behavioral outcomes, laying a solid foundation for her current work in translational medicine. Prior to her Ph.D., she completed an MSc in Molecular Neuroscience from the University of Bristol in 2011, where she specialized in neurodevelopmental and degenerative disorders. Her undergraduate studies were completed at the University of Bedfordshire in 2010, where she earned a BSc (Hons) in Biomedical Science. Dr. Pantouli’s academic trajectory reflects a commitment to interdisciplinary learning and a focus on brain and immune system interactions. Her education combines rigorous training in molecular biology, pharmacology, and neuroscience, empowering her to address complex biomedical questions with a systems-level perspective.

🧪 Experience:

Dr. Pantouli is currently a Postdoctoral Fellow in Vaccine Development Research at the Cleveland Clinic Florida Research and Innovation Center (June 2023 – Present), where she investigates T cell immune responses and develops viral neutralization assays for respiratory viruses including SARS-CoV-2. Previously, she was a Postdoctoral Fellow in the Cancer Research Lab at the same institute (January 2022 – June 2023), where she created innovative murine models of head and neck cancer to evaluate therapeutic efficacy targeting mutant p53. Her research integrates advanced in vivo systems and immune profiling to enhance drug discovery and vaccine evaluation. With a decade-long track record across academia and clinical research centers, Dr. Pantouli has developed robust platforms for translational research, immunotherapeutics, and precision medicine. Her skills span experimental design, animal modeling, immunoassays, and bioanalysis, equipping her to tackle critical gaps in infectious disease and oncology treatment strategies.

🔬 Research Focus:

Dr. Pantouli’s research is centered on translational medicine, focusing on vaccine development, immunotherapy, and molecular pharmacology. Her current projects address immune modulation in viral infections, especially COVID-19, and the development of preclinical assays for vaccine and drug evaluation. She also leads research in oncology, particularly targeting p53 mutations in head and neck squamous cell carcinoma using in vivo models. Her earlier academic work examined the neural and behavioral effects of neuropeptides and receptor modulators in models of autism and Fragile X Syndrome, showing a consistent interest in neuroimmune interactions. She employs a multidisciplinary approach—blending pharmacological, molecular, and immunological tools—to explore how targeted therapies can be optimized for diverse populations. Her work is vital for advancing personalized medicine, especially for aging populations and ethnically diverse cohorts, where vaccine efficacy and immune response can differ significantly.

📚 Publications Top Notes:

  • 🧫 Ethnic differences in COVID-19 T cell immunity responses across variants from Wuhan to Omicron – Accepted in Vaccines

  • 🧠 Evaluation of SR-17018 and oxycodone in the conditioned place preference paradigm using peanut butter chip vehicle – In preparation, Neuropharmacology

  • 🧬 Generation of antigen-specific paired heavy-light chain antibody sequences using large language models – Submitted to Science

  • 💉 COVID-19 Vaccination Enhances the Immunogenicity of Seasonal Influenza Vaccination in the Elderly – Vaccines (2025)

  • 🧩 Tilted striatofugal balance and mGluR4 modulation in the Fmr1 mouse model of Fragile X Syndrome – Under review, Journal of Biological Psychiatry

  • 👃 Acute, chronic and conditioned effects of intranasal oxytocin in mu opioid receptor knockout mice: social context matters – Neuropsychopharmacology (2024)

🧾 Conclusion:

Dr. Fani Pantouli is a highly promising and impactful scientist whose research spans some of the most critical health challenges of our time—infectious diseases, cancer, and neurodevelopmental disorders. Her technical expertise, innovative model development, and deep understanding of immune and neural systems make her an excellent nominee for the Best Researcher Award.

Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Published on by Cell Biologist

Ms. Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Ms. Xiaoyan Wang | Fudan University | China

Dr. Xiaoyan Wang is a dedicated cardiologist and postdoctoral fellow at Fudan University with a strong background in both clinical practice and cardiovascular research. With over a decade of academic training and medical experience, she has built expertise in ventricular remodeling, percutaneous coronary interventions, and immune responses in heart diseases. Under the mentorship of esteemed scholars such as Dr. Yunzeng Zou and Academician Yaling Han, she has published extensively in high-impact journals, reflecting her commitment to scientific advancement. Dr. Wang is currently a scholar in Harvard Medical School’s Global Clinical Scholars Research Training program and also serves as a section editor for the AME Clinical Trials Review. She actively contributes to academic communities, notably by organizing the “Excellent Academic Research Communication Club.” Her work bridges translational medicine and clinical application, aiming to improve cardiovascular patient outcomes through innovative, evidence-based approaches.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Academic Credentials: Dr. Wang has earned her PhD from the prestigious Fudan University and is currently in the Harvard Medical School’s Global Clinical Scholars Research Training Program, signaling a top-tier academic and global research profile.

  2. Dual Research Strength in Basic and Clinical Sciences: She demonstrates an exceptional ability to bridge molecular mechanisms (e.g., immune pathways, cGAS-STING, miRNAs, circular RNAs) with clinical relevance (e.g., myocardial infarction prognosis, anemia impact in PCI), making her work highly translational.

  3. High-Impact Publications: First-author or co-first-author in peer-reviewed journals such as Signal Transduction and Targeted Therapy, Angiology, and Frontiers in Cardiovascular Medicine, with publications tackling cutting-edge cardiovascular topics.

  4. Collaborative and Interdisciplinary Focus: Contributions across institutions and disciplines—partnering with bioinformaticians, clinicians, and molecular scientists—demonstrate strong collaboration skills.

  5. Recognition & Editorial Role: Multiple awards (CPSF Fellowship, Super Postdoc at Fudan) and an editorial position at AME Clinical Trials Review show leadership and peer acknowledgment.

🛠️ Areas for Improvement:

  1. More First-Author Lead on Recent Papers: Although she holds strong co-first authorships and collaborative contributions, maintaining or increasing sole first-author outputs on impactful papers would further strengthen individual scholarly identity.

  2. Increased International Conference Visibility: While she has presented at JCS, continued or expanded visibility in global cardiovascular congresses (e.g., AHA, ESC, ACC) would enhance recognition.

  3. Grant Leadership: Future grant applications as a principal investigator (rather than team member) could affirm her leadership in project design and execution.

🎓 Education :

Dr. Xiaoyan Wang holds a Ph.D. from Fudan University’s Zhongshan Hospital (2016–2019), where she conducted fundamental research on ventricular remodeling under Dr. Yunzeng Zou’s mentorship, supported by prestigious national fellowships. She earned her Master’s degree from Dalian Medical University (2013–2016), focusing on clinical research in percutaneous coronary intervention, under Academician Yaling Han. Her academic foundation was laid with a Bachelor’s degree in Medicine from Fujian Medical University (2007–2012). Currently, she is advancing her research and clinical skills in the prestigious Global Clinical Scholars Research Training Program at Harvard Medical School (2024–2025), blending in-person and online modules. Her multi-tiered education reflects a deep integration of basic science, translational medicine, and clinical practice in cardiovascular health, equipping her to lead high-impact research and patient care initiatives.

💼 Experience:

Dr. Wang is currently a Postdoctoral Fellow at Fudan University (since 09/2023), working under Prof. Yunzeng Zou. She is also the organizer of the Excellent Academic Research Communication Club, promoting interdisciplinary dialogue. From 07/2022 to 07/2023, she served as a cardiologist at Shanghai Jiaotong University’s Ruijin Hospital, and from 2019 to 2022, as a resident in internal medicine at Zhongshan Hospital. In 2024, she began contributing as a section editor for AME Clinical Trials Review, enhancing the quality and visibility of clinical trial research. Her experience spans clinical cardiology, postdoctoral research, editorial responsibilities, and academic leadership. These roles have solidified her ability to translate scientific knowledge into medical practice, particularly in the cardiovascular field.

🏆 Awards & Honors:

Dr. Wang has received numerous accolades recognizing her academic excellence and research impact. In 2023, she was awarded both the Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation (CPSF) and the prestigious Super Postdoctoral Fellowship of Fudan University, underscoring her leadership in postdoctoral research. Her communication and writing skills were acknowledged with the Third Prize in the 8th “Buchang Cup” Young Physician Essay Contest (2019). She also presented Late Breaking Cohort Studies at the Japanese Circulation Society (JCS) Annual Meeting 2019, reflecting international recognition of her scientific contributions. These honors reflect her potential as a rising leader in cardiovascular medicine and support her suitability for the Best Paper Award.

🔬 Research Focus :

Dr. Wang’s research focuses on cardiovascular disease mechanisms, particularly immune system regulation, ventricular remodeling, and the molecular basis of heart failure. Her Ph.D. and postdoctoral studies have addressed the cGAS-STING pathway, miRNA biomarkers, circular RNAs, and inflammation-related signaling in cardiovascular dysfunction. She has also explored clinical prognostic models, such as CHA2DS2-VASc scoring, and interventions including left atrial appendage occlusion and shock wave therapy for ischemic cardiomyopathy. Her dual interest in basic science and clinical outcomes allows her to design translational research that bridges laboratory findings and therapeutic advancements. With a strong publication record and ongoing involvement in global research training at Harvard Medical School, her work aims to inform precision medicine strategies in cardiology.

📚 Publication Titles Top Notes:

  1. 🧠 The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications

  2. 🔗 The connection of immune response and cGAS-STING pathway in cardiovascular disease

  3. 🐭 Left ventricular response in hypertrophy-to-failure transition: roles of Akt, β-arrestin-2, and CaMKII

  4. 💉 Circulating miRNAs in hypertension: diagnostic value and bioinformatics analysis

  5. 🧪 Galectin-3 inhibition improves endothelial progenitor function via autophagy suppression

  6. 🔄 Circular RNA in cardiovascular disease

📌 Conclusion:

Dr. Xiaoyan Wang is highly suitable for the Research for Best Paper Award. Her profile reflects a rare and valuable integration of basic cardiovascular science and clinical innovation, with high-impact, well-cited publications and ongoing international training. Her trajectory, marked by excellence, discipline, and collaborative leadership, meets and exceeds the criteria for this award.

An Dai Tran | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mr. An Dai Tran | Immunology Cellular Interactions | Best Researcher Award

Mr. An Dai Tran, Walailak University, Vietnam

Dr. An Dai Tran is a dedicated medical doctor and emerging public health researcher from Vietnam, currently pursuing a Master’s degree at Walailak University, Thailand. He works at the CDC Dong Thap, focusing on vaccination programs and infectious disease control, including dengue fever, COVID-19, and measles. With several years of hands-on experience in clinical trials and epidemiological research, Dr. Tran has made significant contributions to community health. His published work on vaccination adherence among minority groups in Vietnam has had real-world impact on public health campaigns. Additionally, he has co-developed innovative tools for behavioral science and contributed to machine learning applications in mental health. Collaborating with global institutions such as the University of Queensland and the Pasteur Institute, Dr. Tran’s work reflects a commitment to translational research, public health equity, and data-driven health interventions. His profile is marked by scientific rigor, international collaboration, and service to underserved populations.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Interdisciplinary Research Excellence
    Dr. Tran’s research spans infectious diseases, vaccination behavior, and digital mental health—demonstrating versatility and innovation in addressing modern public health challenges.

  2. Practical and Policy-Relevant Impact
    His work on vaccination adherence in minority communities has real-world implications for national health policy and outreach programs, especially in underserved populations.

  3. Strong Clinical Trial Experience
    He has held critical roles in major vaccine trials (COVID-19 and hand-foot-mouth disease), showing competence in trial design, blinding, and coordination—essential for translational health research.

  4. Collaborative Global Network
    Dr. Tran has established collaborations with renowned institutions such as the University of Queensland and the Pasteur Institute, boosting the credibility and scalability of his research.

  5. Innovation in Mental Health Analytics
    His application of AI and machine learning to post-COVID mental health challenges shows forward-thinking research methodology with future potential.

  6. Published and Cited
    With publications in peer-reviewed journals like Jornal de Pediatria and Journal of Human, Earth, and Future, and a growing citation index, he is building a solid academic foundation.

🛠️ Areas for Improvement:

  1. Broader Indexing and Citations
    While promising, most of his current publications are in emerging or interdisciplinary journals. Publishing in higher-impact, SCI-indexed journals could enhance academic visibility.

  2. Editorial and Peer Review Roles
    Taking on editorial appointments or peer-review duties would strengthen his professional profile and leadership in research.

  3. Mentorship and Teaching Contribution
    Engaging in formal mentorship or academic teaching roles would reflect his potential as a knowledge disseminator and academic influencer.

  4. Expanded Public Health Policy Impact
    Future work that integrates direct contributions to policy development or national programs would further validate his applied research strengths.

🎓 Education:

Dr. An Dai Tran holds a medical degree and is currently completing a Master’s in Public Health at the School of Public Health, Walailak University, Thailand. He was awarded a full scholarship for his postgraduate studies in recognition of his academic excellence and commitment to public health. His education bridges clinical medicine with population-level health sciences, equipping him with multidisciplinary expertise to tackle emerging global health challenges. At Walailak University, Dr. Tran has deepened his knowledge in epidemiology, biostatistics, global health policy, and digital health technologies. His academic training is complemented by a strong foundation in research methodology and ethics, allowing him to conduct high-impact studies and clinical trials. His exposure to both theoretical and practical facets of public health, along with mentorship from international experts, positions him as a future leader in healthcare innovation, with special focus on vaccine-preventable diseases and mental health research in Southeast Asia.

💼 Professional Experience:

Dr. Tran brings valuable on-ground experience through his work at the CDC Dong Thap in Vietnam, where he has led and supported various national vaccination campaigns and infectious disease monitoring systems. He has been actively involved in both the operational and research aspects of public health interventions. His clinical trial roles include coordinating blinded and double-blinded studies on COVID-19 and hand-foot-mouth vaccines. Notably, he served as a research coordinator in large-scale, placebo-controlled trials with rigorous ethical and methodological frameworks. His consultancy record includes four projects in collaboration with governmental and academic institutions, such as the University of Queensland (E-Dengue Project) and the Pasteur Institute (Vietnam-based vaccine research). Dr. Tran’s experience spans public health research, disease surveillance, behavioral analysis, and machine learning for mental health prediction. His combined roles as physician, coordinator, and academic researcher highlight his versatility, responsibility, and drive for impactful health innovations that reach marginalized communities.

🧠 Research Focus:

Dr. Tran’s research lies at the intersection of infectious diseases, vaccination behavior, and digital mental health. His primary interest is understanding the behavioral and sociocultural factors affecting vaccine uptake, particularly among ethnic minority populations. His first-author publication on this topic has already contributed to improved regional strategies for vaccine delivery. Expanding into digital health, Dr. Tran has co-developed psychological assessment tools and applied machine learning to detect mental health issues in post-COVID patients. His work in computational psychiatry includes Reddit-based community sentiment analysis and comparative modeling for long COVID mental health prediction. By merging AI with public health, he aims to enhance early detection and intervention systems. His approach reflects a holistic vision—bridging clinical practice, community outreach, and technology—with a commitment to healthcare equity. Dr. Tran’s research is not only academically sound but also practically applicable, aligning with Sustainable Development Goals (SDGs) for health and well-being.

📚 Publications Top Notes:

  1. 🧬 Parental predictors of childhood vaccination adherence in border areas of Southern Vietnam – Jornal de Pediatria.

  2. 🏃‍♂️ Initial Construction of the Exercise Maintenance Motivation Scale: A Mixed Method Study – Journal of Human, Earth, and Future.

  3. 🤖 An Analysis of Machine Learning for Detecting Depression, Anxiety, and Stress of Recovered COVID-19 Patients – Journal of Human, Earth, and Future.

  4. 🧠 Exploring Mental Stress Expressions in Online Communities: A Subreddit Analysis – Journal of Human, Earth, and Future.

  5. 🧪 Mental health and long COVID status prediction among recovered COVID-19 patients: A comparison of machine learning methods – Journal of Human, Earth, and Future.

🧾 Conclusion:

Dr. An Dai Tran is a highly promising early-career researcher whose interdisciplinary work in public health is both scientifically rigorous and socially impactful. His blend of clinical trial expertise, digital health innovation, and public health behavior research makes him an ideal candidate for the Best Researcher Award. While there is room to grow in areas like journal prestige and academic leadership, his current trajectory, achievements, and commitment to health equity clearly demonstrate award-worthy excellence.